ERIN LAGROUE: Open Payments
NPI 1538471495 · WALKER, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,292 in 121 payments from 21 companies in 2025. Trend: 2023 $2,400 · 2024 $2,139 · 2025 $2,292
Food & beverage: $2,292
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $246 |
| GlaxoSmithKline, LLC. | 14 | $242 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $225 |
| Axsome Therapeutics, Inc. | 12 | $225 |
| PFIZER INC. | 11 | $198 |
| Lilly USA, LLC | 11 | $180 |
| ABBVIE INC. | 10 | $172 |
| AstraZeneca Pharmaceuticals LP | 4 | $156 |
| Phathom Pharmaceuticals, Inc. | 9 | $124 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $113 |
Products named: Kerendia, TRELEGY ELLIPTA, Auvelity, AIRSUPRA, MOUNJARO, VOQUEZNA, XIFAXAN, Ozempic.
Industry payments across LA — which companies pay providers there.
